Stempoint Capital’s Palisade Bio PALI Stock Holding History

Stempoint Capital’s Portfolio PALI Stock Details PALI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4,192,375	Closed	-$9.85M	–	109
2025 Q4	$9.85M	Buy	+4,192,375	New	+$8.06M	1.69%	18

Other funds holding PALI

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

BGI

B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Stempoint Capital's PALI Position: Q1 2026 in Review

Stempoint Capital sold out of Palisade Bio (PALI) in Q1 2026, closing a stake of 4,192,375 shares — an estimated $9.85M sold.

Stempoint Capital first reported a position in PALI in Q4 2025 and held it in 1 quarter. The position peaked at $9.85M in Q4 2025. 96 funds tracked by Wall St. Rank hold PALI as of Q1 2026.

Stempoint Capital reported no remaining Palisade Bio position as of Q1 2026 after selling out during the quarter.
Stempoint Capital sold 4,192,375 Palisade Bio shares in Q1 2026, an estimated $9.85M.
Stempoint Capital first reported a position in Palisade Bio in Q4 2025 and held it in 1 quarter.
Stempoint Capital's Palisade Bio position peaked at $9.85M in Q4 2025.
96 funds tracked by Wall St. Rank held Palisade Bio as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.